Genvara Biopharma
- Biotech or pharma, therapeutic R&D
Genvara is a late-stage cardiovascular company with a Phase 3-ready drug therapy. Genvara specializes in identifying common genetic variation that can be therapeutically targeted (“pharmacogenetics”) in cardiovascular disorders. Our basic and clinical research programs focus on human cardiac systems in order to provide a direct path from discovery to clinical application, utilizing our decades-long experience in molecular genetics, molecular pharmacology, clinical trials and drug development. Genvara's late-stage lead drug asset, GENCARO™, is a small molecule therapy for the treatment of Atrial Fibrillation in Heart Failure, a clear unmet medical need. This drug is targeted to patients with the favorable genetic profile in terms of response, representing around 65% of the overall population. GENCARO™ is one small, cost-effective pivotal trial away from approval.
Address
WestminsterColorado
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}